Clinical Trials in Italy — Country Dashboard | 3,681 EU Studies

Filter these 3,681 trials by condition, phase, sponsor and more.

Open in Search →

3,681 Registered trials

1,489 Recruiting

1,842 Completed trials

891 Sponsors active

775 Research sites

Phase III

Phase II

Phase III: 1645 Phase II/III: 152 Phase II: 1113 Phase I/II: 212 Phase III/IV: 28 Phase IV: 153 Phase I: 119 Phase I (Other): 111 Phase I (FiH): 142 Other: 5 Other: 1

Oversight events in trials active here:

107 serious breaches 827 temporary halts 64 urgent safety measures 84 unexpected events 162 corrective measures across 455 trials

View oversight register →

Top conditions

Non-small cell lung cancer 135 Non-small cell lung cancer metastatic 50 Ovarian cancer 32 Diffuse large B-cell lymphoma 27 Breast cancer 27 Crohn's disease 26 Colorectal cancer 26 Endometrial cancer 25 Prostate cancer metastatic 23 Systemic lupus erythematosus 22 Myasthenia gravis 21 Asthma 20

Top sponsors

Merck Sharp & Dohme LLC 180 AstraZeneca AB 161 Novartis Pharma AG 145 F. Hoffmann-La Roche AG 138 Janssen - Cilag International 93 AbbVie Deutschland GmbH & Co. KG 88 Sanofi-Aventis Recherche & Developpement 75 Bristol-Myers Squibb Services Unlimited Company 64 Pfizer Inc. 63 Amgen Inc. 60 Glaxosmithkline Research & Development Limited 60 Boehringer Ingelheim International GmbH 49

Cities with most trials

All 250 cities →

All trials — page 4

3,681 total

A Double-Blinded, Placebo-Controlled Exploratory Study to Investigate the Efficacy and Safety of Flexible dosing of Oral Lidocaine (ORE-001)… Pending

2023-510499-30-00 Phase II Anorexia nervosa Orexa B.V.
Study of Oral Weekly GS-1720 and GS-4182 Versus Biktarvy in People With HIV-1 Who Are Virologically Suppressed Pending

2024-511054-50-00 Phase II/III HIV-1 Infection Gilead Sciences Inc.
A Study of Anti-CD19 CAR T-cell Therapy, in Subjects With Refractory Primary and Secondary Progressive Multiple Sclerosis Pending

2024-511168-10-00 Phase II Primary or Secondary Progressive Multiple Sclerosis Kyverna Therapeutics Inc.
Activity of Pembrolizumab plus Enfortumab Vedotin in Collecting Duct and Renal Medullary Carcinoma (REPRINT trial) Pending

2024-511587-93-00 Phase II Medullary Renal cell Carcinoma Fondazione IRCCS Istituto Nazionale Dei Tumori
An Open-Label Extension Study to Evaluate the Long-term Safety and Efficacy of BMN 351 in Participants with Duchenne Muscular Dystrophy Pending

2024-511656-41-00 Phase II Duchenne Muscular Dystrophy Biomarin Pharmaceutical Inc.
ARMYDA TICA-MI study Pending

2024-511944-18-01 Phase IV ST-elevation myocardial infarction (STEMI) undergoing primar… Azienda Ospedaliero-Universitaria Maggiore Della Carita
A trial to learn how well Dato-DXd and rilvegostomig work and how safe they are in participants with stage I adenocarcinoma non-small cell l… Pending

2024-512195-35-00 Phase III Stage I adenocarcinoma non-small cell lung cancer (NSCLC) wi… AstraZeneca AB
A randomized, double-blind, placebo-controlled, 104-week proof-of-concept study to evaluate the efficacy of intravenous prasinezumab in part… Pending

2024-513496-40-00 Phase II PARKINSON’S DISEASE Universitaetsklinikum Tuebingen AöR
A Phase 1/2a Dose-Escalating Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ARO-DM1 in Subjects With … Pending

2024-513579-42-00 Phase I (FiH) Type 1 Myotonic Dystrophy Sarepta Therapeutics Inc.
Extension Study of ACT-EARLY Pending

2024-513676-18-00 Phase III Transthyretin Amyloidosis Eidos Therapeutics Inc.
SIOP PNET 5 medulloblastoma Pending

2024-513724-42-00 Phase II/III Medulloblastoma University Medical Center Hamburg-Eppendorf
DORAL Pending

2024-513941-35-00 Phase I/II HIV Disease Centre de Recherches et d’Etudes sur les Pathologies Infectieuses, Tropicales et…
Temporal kinetics of antibody and cellular response markers and relative impact of revaccination in patients recovered from COVID-19 after t… Pending

2024-514071-17-00 Phase IV Covid-19 infection National Institute For Infectious Diseases Lazzaro Spallanzani
A study to find an efficacious and safe dose of CHF10067 (zampilimab) in participants with idiopathic pulmonary fibrosis Pending

2024-514246-37-00 Phase II Idiopathic pulmonary fibrosis (IPF) Chiesi Farmaceutici S.p.A.
A 52 week study in which neither Sponsor or participant know the treatment assigned to subjects to compare the experimental drug (CHF 5993) … Pending

2024-514248-95-00 Phase III Uncontrolled Asthma Chiesi Farmaceutici S.p.A.
The impact of PDD during TURB for NMIBC: a prospective randomized controlled trial Pending

2024-514316-27-00 Phase IV Not muscular invasive bladder cancer Azienda Ospedaliera Universitaria Citta Della Salute E Della Scienza Di Torino
PIrfenidone to prevent fibrOsis in ARDS. A RaNdomizEd controllEd tRial - PIONEER Pending

2024-514355-16-01 Phase III Acute Respiratory Distress Syndrome (ARDS) Ospedale San Raffaele S.r.l.
A randomized phase II study of Pembrolizumab (MK-3475) as maintainance therapy in patients with unresectable stage III non-small cell lung … Pending

2024-514701-57-01 Phase II non Small Cell Lung Cancer Universita' Degli Studi Di Torino
TOTAL NEOADJUVANT TREATMENT WITHOUT SURGERY FOR LOCALLY ADVANCED RECTAL CANCER: PROSPECTIVE CLINICAL TRIAL TO ASSESS TUMOR COMPLETE RESPONSE… Pending

2024-515225-28-00 Phase II/III Adenocarcinoma of the medium/lower rectum in Stage II (cT3-4… ASST Grande Ospedale Metropolitano Niguarda
A Randomized Double-Blind, Placebo Controlled Trial of Abatacept (CTLA4-Ig) in Giant Cell Arteritis (ABAGART) Pending

2024-515287-31-00 Phase III Giant Cell Arteritis Trustees Of The University Of Pennsylvania
Targeting inflammation to reduce 90-day and 1-year postoperative severe morbidity in patients with unfavorable inflammatory profile undergoi… Pending

2024-515333-14-03 Phase II Patients scheduled for major surgery for oncologic indicatio… Fondazione IRCCS Istituto Nazionale Dei Tumori
A Long-Term Extension Study to Evaluate the Safety and Efficacy of Ritlecitinib in Participants With Severe AA Who Have Completed Studies B7… Pending

2024-515439-31-00 Phase III Alopecia areata Pfizer Inc.
A Phase 2 Study of NEU-411 in Companion Diagnostic-Positive Participants with Early Parkinson’s Disease Pending

2024-515448-22-00 Phase II Parkinson Disease, Idiopathic Neuron23 Inc.
Long-term impact of GBCAs on motor and cognitive function following repeated Contrast-Enhanced MRI—ODYSSEY Pending

2024-515462-14-00 Phase IV Long term potential effect of repeated exposure to either a … Iqvia Rds France

Showing 73–96 of 3,681 trials

← All countries